Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

1ISG-016 Ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis in a national health system: a cost effectiveness analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CLC LamestaRPR PettiPVP Volpi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lamesta et al. (2024) studied this question.

synapsesocial.com/papers/68e7660bb6db6435876db9e2https://doi.org/10.1136/ejhpharm-2024-eahp.28
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systematic review on Ocrevus for treatment of multiple sclerosis2024 · 1 citations
  2. 2Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study2026 · 1 citations
  3. 3Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations
  4. 4Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study2024 · 6 citations
  5. 5Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis2025